Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

NCT06570447 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma-Recurrent
Diffuse Large B-Cell Lymphoma-Refractory

Interventions

DRUG: Glofitamab
DRUG: Chidamide

Sponsor

Tianjin Medical University Cancer Institute and Hospital